XML 96 R82.htm IDEA: XBRL DOCUMENT v3.19.2
Pro Forma Financial Statements (Details 1) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2018
Dec. 31, 2017
Revenues $ 212,242
Cost of revenues 1,499
Gross profit 210,743
Operating expenses        
Selling, general and administrative expenses 510,803 420,462 695,148 811,685
Research and development expenses 421,956 248,111 669,668 3,171,665
Stock based compensation 8,550 5,626 28,800 155,400
Total operating expenses 941,309 674,199 1,393,616 4,138,750
Loss from operations (730,566) (674,199) (1,393,616) (4,138,750)
Other income (expense)        
Interest income 189 1,150 93 180
Interest Expense (129,886) (106,854) (155,930) (103,460)
Rental income (3,891) 3,066
Investment loss (66,205) (38,567) (549)
Gain/Loss on foreign exchange changes (3) 7,515
Total other income (expenses) (200,296) (133,705) (2,705,837) (103,280)
Loss before provision for income tax (930,862) (807,904) (4,099,453) (4,242,030)
Provision for income tax (benefit) (57,545) (94,282) 1,850 830
Net loss attributable to ABVC and subsidiaries (873,317) (713,622) (4,101,303) (4,242,860)
Foreign currency translation adjustment (86,786) 64,994
Comprehensive Income (Loss) $ (878,457) $ (536,393)
Net loss per share attributable to common stockholders        
Basic and diluted $ (0.05) $ (0.05) $ (0.02) $ (0.02)
Weighted average number of common shares outstanding        
Basic and diluted 14,965,665 11,599,911 213,884,105 213,321,921
Pro Forma Adjustment [Member]        
Revenues      
Cost of revenues      
Gross profit      
Operating expenses        
Selling, general and administrative expenses      
Research and development expenses      
Stock based compensation      
Total operating expenses      
Other income (expense)        
Interest income      
Interest Expense      
Rental income      
Impairment loss      
Investment loss      
Gain/Loss on foreign exchange changes      
Gain/Loss on investment in equity securities      
Other income (expense)      
Total other income (expenses)      
Loss before provision for income tax      
Provision for income tax (benefit)      
Net loss      
Net loss attributable to noncontrolling interests      
Net loss attributable to ABVC and subsidiaries      
Foreign currency translation adjustment      
Comprehensive Income (Loss)      
Net loss per share attributable to common stockholders        
Basic and diluted      
Weighted average number of common shares outstanding        
Basic and diluted      
Pro Forma [Member]        
Revenues     $ 517,153  
Cost of revenues     190,089  
Gross profit     327,064  
Operating expenses        
Selling, general and administrative expenses     2,258,040  
Research and development expenses     1,419,638  
Stock based compensation     28,800  
Total operating expenses     3,706,478  
Loss from operations     (3,379,414)  
Other income (expense)        
Interest income     9,810  
Interest Expense     (462,751)  
Rental income     11,924  
Impairment loss     (63,663)  
Investment loss     (396,025)  
Gain/Loss on foreign exchange changes     7,307  
Gain/Loss on investment in equity securities     (2,741,914)  
Other income (expense)     (4,524)  
Total other income (expenses)     (3,639,836)  
Loss before provision for income tax     (7,019,250)  
Provision for income tax (benefit)     (364,297)  
Net loss     (6,654,953)  
Net loss attributable to noncontrolling interests     489,151  
Net loss attributable to ABVC and subsidiaries     (7,144,104)  
Foreign currency translation adjustment     86,786  
Comprehensive Income (Loss)     $ (7,230,890)  
Net loss per share attributable to common stockholders        
Basic and diluted     $ (0.03)  
Weighted average number of common shares outstanding        
Basic and diluted     214,156,988  
ABVC [Member]        
Revenues      
Cost of revenues      
Gross profit      
Operating expenses        
Selling, general and administrative expenses     695,148  
Research and development expenses     669,668  
Stock based compensation     28,800  
Total operating expenses     1,393,616  
Loss from operations     (1,393,616)  
Other income (expense)        
Interest income     93  
Interest Expense     (155,930)  
Rental income      
Impairment loss      
Investment loss     (549)  
Gain/Loss on foreign exchange changes      
Gain/Loss on investment in equity securities     (2,549,451)  
Other income (expense)      
Total other income (expenses)     (2,705,837)  
Loss before provision for income tax     (4,099,453)  
Provision for income tax (benefit)     1,850  
Net loss     (4,101,303)  
Net loss attributable to noncontrolling interests      
Net loss attributable to ABVC and subsidiaries     (4,101,303)  
Foreign currency translation adjustment      
Comprehensive Income (Loss)     $ (4,101,303)  
Net loss per share attributable to common stockholders        
Basic and diluted     $ (0.02)  
Weighted average number of common shares outstanding        
Basic and diluted     213,884,105  
BioKey [Member]        
Revenues     $ 510,197  
Cost of revenues     4,809  
Gross profit     505,388  
Operating expenses        
Selling, general and administrative expenses     669,322  
Research and development expenses     430,917  
Stock based compensation      
Total operating expenses     1,100,239  
Loss from operations     (594,851)  
Other income (expense)        
Interest income     4,598  
Interest Expense      
Rental income      
Impairment loss      
Investment loss      
Gain/Loss on foreign exchange changes      
Gain/Loss on investment in equity securities      
Other income (expense)     630  
Total other income (expenses)     5,228  
Loss before provision for income tax     (589,623)  
Provision for income tax (benefit)     800  
Net loss     (590,423)  
Net loss attributable to noncontrolling interests      
Net loss attributable to ABVC and subsidiaries     (590,423)  
Foreign currency translation adjustment      
Comprehensive Income (Loss)     $ (590,423)  
Net loss per share attributable to common stockholders        
Basic and diluted      
Weighted average number of common shares outstanding        
Basic and diluted      
BioLite [Member]        
Revenues     $ 6,956  
Cost of revenues     185,280  
Gross profit     (178,324)  
Operating expenses        
Selling, general and administrative expenses     893,570  
Research and development expenses     319,053  
Stock based compensation      
Total operating expenses     1,212,623  
Loss from operations     (1,390,947)  
Other income (expense)        
Interest income     5,119  
Interest Expense     (306,821)  
Rental income     11,924  
Impairment loss     (63,663)  
Investment loss     (395,476)  
Gain/Loss on foreign exchange changes     7,307  
Gain/Loss on investment in equity securities     (192,463)  
Other income (expense)     (5,154)  
Total other income (expenses)     (939,227)  
Loss before provision for income tax     (2,330,174)  
Provision for income tax (benefit)     (366,947)  
Net loss     (1,963,227)  
Net loss attributable to noncontrolling interests     489,151  
Net loss attributable to ABVC and subsidiaries     (1,474,067)  
Foreign currency translation adjustment     86,786  
Comprehensive Income (Loss)     $ (1,560,862)  
Net loss per share attributable to common stockholders        
Basic and diluted      
Weighted average number of common shares outstanding        
Basic and diluted